Design Therapeutics (DSGN) Change in Accured Expenses (2020 - 2026)

Design Therapeutics (DSGN) has 7 years of Change in Accured Expenses data on file, last reported at -$2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 734.22% year-over-year to -$2.5 million; the trailing twelve-month figure through Mar 2026 stood at $2.3 million (up 126.92% YoY), and the FY2025 full-year result was $4.5 million, up 468.01% from the prior year.
• Change in Accured Expenses declined to -$2.5 million in Q1 2026, from $1.8 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $3.2 million in Q3 2022 to a low of -$2.8 million in Q4 2023.
• A 5-year average of $288823.5 and a median of $423000.0 in 2022 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses surged 1726.92% in 2022 and slumped 911.63% in 2023, its largest moves.
• Tracing DSGN's Change in Accured Expenses over 5 years: stood at $423000.0 in 2022, then slumped by 764.3% to -$2.8 million in 2023, then soared by 135.84% to $1.0 million in 2024, then surged by 82.72% to $1.8 million in 2025, then sank by 236.47% to -$2.5 million in 2026.
• Business Quant data shows DSGN's Change in Accured Expenses at -$2.5 million in Q1 2026, $1.8 million in Q4 2025, and $2.4 million in Q3 2025.